Stock Watch: SIRI, ACTC.PK, BMSN.OB, CSUH.OB, CRYP
There are no Focus articles on BMSN.
There are no Transcripts on BMSN.
Marketwire (Aug 1, 2014)
Mon, May. 12, 1:52 PM
- Bio-Matrix Scientific Group (BMSN +70.8%) subsidiary Regen BioPharma provides an update on its follow up on the FDA's issues regarding its HemaXellerate IND. On March 6, 2014 the company submitted a protocol modification, additional details on manufacturing, new data on the therapeutic effects of HemaXellerate I in animal models of diseases similar to aplastic anemia in humans and additional safety data to the FDA.
- The agency accepted the clinical protocol and product manufacturing information but requested clarification on the animal safety studies.
- On May 9, the company updated the IND and submitted it to the FDA for review.
BMSN vs. ETF Alternatives
Bio-Matrix Scientific Group Inc. is a biotechnology research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology,... More
Other News & PR